相关实验视频
Updated: Jan 14, 2026

07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
904
因弗利西马布诱导的有组织性肺炎导致持续性呼吸系统障碍
1Department of Internal Medicine, The Vancouver Clinic and Legacy Salmon Creek Medical Center, Vancouver, WA.
ACG case reports journal
|October 20, 2025
概括
恩弗利西马布治疗性结肠炎,但可能导致肺损伤. 这项研究调查了因弗利西马布诱导的严重肺炎及其长期呼吸系统影响,目前人们对其了解甚少.
科学领域:
- 肺部病理学 肺部病理学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 恩弗利西马布是一种针对中度至重度性结肠炎的TNF细胞因子信号传递的生物药物.
- TNF 抑制剂可能会导致免疫抑制并损害组织修复.
- 病例报告表明,infliximab与急性肺毒性有关.
研究的目的:
- 为了描述因弗利克西马布诱导的严重肺炎的可能性.
- 为了评估与因弗利克西马布治疗相关的长期呼吸系统损伤.
主要方法:
- 对因弗力西马布诱导的肺毒性现有文献的综述.
- 分析详细描述严重肺炎的病例报告.
- 对长期呼吸道结果的评估.
主要成果:
- 在急性肺毒性中Infliximab的作用已得到证实.
- 严重的肺炎是一种潜在的不良影响.
- 长期呼吸系统障碍的数据有限.
结论:
- 需要进一步的研究才能充分理解因弗利西马布诱导的肺炎.
- 长期的呼吸系统后果需要全面的描述.
- 在接受infliximab的患者中,对肺部不良事件的临床警至关重要.
相关概念视频
Pneumonia IV: Management
751
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
751
Pneumonia II: Pathophysiology
2.6K
The pathophysiology of pneumonia involves the following steps:
2.6K
Pneumonia I: Introduction
723
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
723
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Pneumonia III: Complications and Assessment
777
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
777
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.5K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.5K

